Genenta Science S.p.A.
Support and Resistance Levels
Past performance
News About GNTA
All events for GNTA
All deals for GNTA
Financial Ratios
Financial Statements
GNTA vs Sector & Peers
About Genenta Science S.p.A.
Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy. Website genenta.com
Headquarters Milan, MI, IT